References
- Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BMJ. 2008;336(7654):1185–1189.
- Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med. 1998;338(17):1202–1211.
- National Institute of Diabetes and Digestive and Kidney Diseases: National Institutes of Health. Nephrotic syndrome in adults; 2014 [cited 2020 Aug 18]. Available from: https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults.
- Bomback AS, Tumlin JA, Baranski J, et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Dev Ther. 2011;5:147–153.
- Madan A, Mijovic-Das S, Stankovic A, et al. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series. BMC Nephrol. 2016;17(1):37.
- Bomback AS, Canetta PA, Beck LH, Jr, et al. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol. 2012;36(1):58–67.
- Pilon D, Sheehan JJ, Szukis H, et al. Medicaid spending burden among beneficiaries with treatment-resistant depression. J Comp Eff Res. 2019;8(6):381–392.
- Tumlin JA, Galphin CM, Rovin BH. Steroid resistant nephrotic syndrome: a prospective, open label study of the safety and efficacy of combination tacrolimus and ACTHar gel therapy [ASN abstract FR-PO434]. J Am Soc Nephrol. 2015;26(Suppl):455A.
- Tumlin JA, Rovin BH, Paxton WG, et al. A prospective, open label study of the safety and treatment efficacy of ACTHar gel for fibrillary glomerulonepritis [ASN abstract SA-PO659]. J Am Soc Nephrol. 2016;27(Suppl):781A.
- Tumlin J, Galphin C, Santos R, et al. Safety and efficacy of combination ACTHar gel and tacrolimus in treatment-resistant focal segmental glomerulosclerosis and membranous glomerulopathy. Kidney Int Rep. 2017;2(5):924–932.
- Madan A. Repository corticotropin injection in a patient presenting with focal segmental glomerulosclerosis, rheumatoid arthritis, and optic neuritis: a case report. Int J Gen Med. 2015;8:119–124.
- Madan A, Mijovic-Das S, Stankovic A, et al. Treatment response to Acthar Gel in patients with idiopathic focal segmental glomerulosclerosis and idiopathic membranous nephropathy: a retrospective case series [ASN abstract TH-PO437]. J Am Soc Nephrol. 2014;25(Suppl):206A.
- Reuben S, Maroz N. Treatment of Fibrillary Glomerulonephritis with Use of Repository Corticotropin Injection (Acthar) [ASN abstract TH-PO018]. J Am Soc Nephrol. 2016;27(Suppl):99A.
- Bonilla NA, Parada XF, Henriquez MA. A case series on the treatment of nephrotic syndrome with adrenocorticotropin hormone (ACTH) gel in an office setting [ASN abstract PUB219]. J Am Soc Nephrol. 2015;26(Suppl):937A.
- Filippone EJ, Dopson SJ, Rivers DM, et al. Adrenocorticotropic hormone analog use for podocytopathies. IMCRJ. 2016;9:125–133.
- Marayati F, Long-Term HP. Acthar gel treatment of relapsing idiopathic membranous glomerulopathy: a case study [ASN abstract PUB206]. J Am Soc Nephrol. 2015;26(Suppl):934A.
- McMahon BA, Berliner AR. Treatment of severe resistant idiopathic membranous glomerulopathy with adrenocorticotropic hormone gel: a case report [ASN abstract SA-PO032]. J Am Soc Nephrol. 2015;26(Suppl):631A.
- Hladunewich MA, Cattran D, Beck LH, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transplant. 2014;29(8):1570–1577.
- Lieberman KV, Pavlova-Wolf A. Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance. J Nephrol. 2017;30(1):35–44.
- Hogan J, Bomback AS, Mehta K, et al. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol. 2013;8(12):2072–2081.
- Park Y, Raza S, George A, et al. The effect of formulary restrictions on patient and payer outcomes: a systematic literature review. J Manag Care Spec Pharm. 2017;23(8):893–901.
- Rice JB, Panaccio MP, White A, et al. Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection for acute exacerbations of multiple sclerosis. Neurol Ther. 2020. DOI:10.1007/s40120-020-00219-y
- Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424.
- Nazareth TA, Kariburyo F, Kirkemo A, et al. Patients with idiopathic membranous nephropathy: a real-world clinical and economic analysis of U.S. claims data. J Manag Care Spec Pharm. 2019;25(9):1011–1020.